Stock Market News
Hutchison seeks approval for cancer drug after trial success
Cancer drug development company Hutchison China Meditech plans to gain approval for its fruquintinib drug as China's first Tyrosine-Kinase inhibitor (TKI), the company said on Monday.
Fruquintinib passed a phase three study in colorectal cancer last year and has been submitted to China's centre for drug evaluation as of June 2017, with approval subject to technical reviews and manufacturing inspections.
Trials using the drug, which inhibits cancer cells' ability to adapt against treatments, for the treatment of gastric cancer and some forms of non-small cell lung cancer are currently underway, while trials for a second TKI named Savolitinib are also underway for the treatment of lung cancer.
Simon To, chairman of Hutchison China Meditech, said: "In our innovation platform, we have progressed our deep portfolio of eight clinical drug candidates, now in active or completing clinical trials in 36 TPPs around the world. Two major milestones were the formal NDA submission for fruquintinib in CRC in China; and the initiation of our first global Phase III registration study of savolitinib in c-MET-driven metastatic PRCC."
Meanwhile, the company also reported its financial results for 2017 on Monday, revealing a 12% increase in revenues to $241.2m compared to the previous year and a net loss of $26.7m compared to a profit of $11.7m.
The loss can largely be attributed to the company's $88m investment in research and development, up 16% on the previous year, as the company proceeds with clinical trials and drug development.
At 31 December, the company holds cash resources of $479.6m including cash and cash equivalents, short term investments and unutilized bank facilities compared to $173.7m at the same point in 2016.
As of 1635 GMT, Hutchison China Meditech's shares were up 2.16% at 5200.00p
Fruquintinib passed a phase three study in colorectal cancer last year and has been submitted to China's centre for drug evaluation as of June 2017, with approval subject to technical reviews and manufacturing inspections.
Trials using the drug, which inhibits cancer cells' ability to adapt against treatments, for the treatment of gastric cancer and some forms of non-small cell lung cancer are currently underway, while trials for a second TKI named Savolitinib are also underway for the treatment of lung cancer.
Simon To, chairman of Hutchison China Meditech, said: "In our innovation platform, we have progressed our deep portfolio of eight clinical drug candidates, now in active or completing clinical trials in 36 TPPs around the world. Two major milestones were the formal NDA submission for fruquintinib in CRC in China; and the initiation of our first global Phase III registration study of savolitinib in c-MET-driven metastatic PRCC."
Meanwhile, the company also reported its financial results for 2017 on Monday, revealing a 12% increase in revenues to $241.2m compared to the previous year and a net loss of $26.7m compared to a profit of $11.7m.
The loss can largely be attributed to the company's $88m investment in research and development, up 16% on the previous year, as the company proceeds with clinical trials and drug development.
At 31 December, the company holds cash resources of $479.6m including cash and cash equivalents, short term investments and unutilized bank facilities compared to $173.7m at the same point in 2016.
As of 1635 GMT, Hutchison China Meditech's shares were up 2.16% at 5200.00p
Related share prices |
---|
Hutchison China Meditech Ltd (HCM) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price